Literature DB >> 9816286

Loss of heterozygosity at 3p in non-small cell lung cancer and its prognostic implication.

T Mitsudomi1, T Oyama, K Nishida, A Ogami, T Osaki, K Sugio, K Yasumoto, K Sugimachi, A F Gazdar.   

Abstract

We examined 110 patients with non-small cell lung cancer who underwent consecutive pulmonary resection for loss of heterozygosity (LOH) at the short arm of chromosome 3 (3p). We performed a PCR-based microsatellite polymorphism analysis for detection of LOH. The microsatellite markers used were D3S966 (3p21.3), D3S1007 (3p21. 3-22), and D3S1228 (3p14.1-14.3). Of 98 informative cases, 3p LOH was found in 45 (46%). 3p LOH was more prevalent in squamous cell carcinoma (24/35, 69%) than in adenocarcinoma (18/52, 35%; P = 0.0019). There was no significant association between 3p LOH and sex, disease stage, or grade of differentiation. However, patients with 3p LOH tended to survive for a shorter period of time (P = 0.0631, log rank test). There was no such tendency in squamous cell carcinoma (P = 0.7513), but in adenocarcinoma, the difference of survival was significant (P = 0.0015). Cox's proportional hazards model also predicted that 3p LOH was an independent poor prognostic marker in adenocarcinoma (P = 0.0502) but not in squamous cell carcinoma or in the entire cohort (P = 0.7866 and 0.1371, respectively). LOH at 3p may help to identify non-small cell lung cancer patients with a poor prognosis, who thus need an intensive postoperative follow-up protocol or who are suitable for novel investigational therapeutic approaches. It is also suggested that the putative tumor suppressor gene at 3p may have a different role in squamous cell carcinoma and adenocarcinoma of the lung.

Entities:  

Mesh:

Year:  1996        PMID: 9816286

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  15 in total

1.  Inactivation of RASSF1A, the tumor suppressor gene at 3p21.3 in extrahepatic cholangiocarcinoma.

Authors:  Yong-Jun Chen; Qi-Bin Tang; Shen-Quan Zou
Journal:  World J Gastroenterol       Date:  2005-03-07       Impact factor: 5.742

Review 2.  Lung cancer in never-smokers.

Authors:  Chee-Keong Toh; Wan-Teck Lim
Journal:  J Clin Pathol       Date:  2006-08-17       Impact factor: 3.411

3.  Molecular biological markers and micrometastasis in resected non-small-cell lung cancer. Prognostic implications.

Authors:  T Osaki; T Oyama; M Inoue; C D Gu; M Kodate; M Aikawa; T So; M Mizukami; T Mitsudomi; K Yasumoto
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2001-09

Review 4.  Biological and clinical implications of EGFR mutations in lung cancer.

Authors:  Tetsuya Mitsudomi; Takayuki Kosaka; Yasushi Yatabe
Journal:  Int J Clin Oncol       Date:  2006-06       Impact factor: 3.402

5.  Prognostic impact of telomerase activity in non-small cell lung cancers.

Authors:  S Taga; T Osaki; A Ohgami; H Imoto; K Yasumoto
Journal:  Ann Surg       Date:  1999-11       Impact factor: 12.969

6.  Evidence-based prevention (EBP): A review of cytochrome P450 expression in the bronchial epithelium and new approach to lung cancer prevention.

Authors:  Tsunehiro Oyama; Toyohi Isse; Tomoe Murakami; Rie Suzuki-Narai; Masanori Ogawa; Tetsunosuke Yamaguchi; Tsuyoshi Kinaga; Yasunori Yashima; Shinichi Ozaki; Yong-Dae Kim; Heon Kim; Toshihiro Kawamoto
Journal:  Environ Health Prev Med       Date:  2006-05       Impact factor: 3.674

Review 7.  Mutations in the epidermal growth factor receptor gene and effects of EGFR-tyrosine kinase inhibitors on lung cancers.

Authors:  Takayuki Fukui; Tetsuya Mitsudomi
Journal:  Gen Thorac Cardiovasc Surg       Date:  2008-03-14

8.  MicroRNA expression differentiates histology and predicts survival of lung cancer.

Authors:  Maria Teresa Landi; Yingdong Zhao; Melissa Rotunno; Jill Koshiol; Hui Liu; Andrew W Bergen; Maurizia Rubagotti; Alisa M Goldstein; Ilona Linnoila; Francesco M Marincola; Margaret A Tucker; Pier Alberto Bertazzi; Angela C Pesatori; Neil E Caporaso; Lisa M McShane; Ena Wang
Journal:  Clin Cancer Res       Date:  2010-01-12       Impact factor: 12.531

9.  Evaluation of loss of heterozygosity and microsatellite instability in human pterygium: clinical correlations.

Authors:  E T Detorakis; G Sourvinos; J Tsamparlakis; D A Spandidos
Journal:  Br J Ophthalmol       Date:  1998-11       Impact factor: 4.638

10.  Impact of thymidylate synthase protein expression on efficacy of chemotherapy in advanced lung cancer patients.

Authors:  Yoshiko Nakagawa; Tetsuo Shimizu; Noriaki Takahashi; Shu Hashimoto
Journal:  Mol Clin Oncol       Date:  2013-03-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.